Literature DB >> 12023553

Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs.

Jason D Kilts1, Hilary S Connery, Elaine G Arrington, Mechelle M Lewis, Cindy P Lawler, Gerry S Oxford, Karen L O'Malley, Richard D Todd, Bonita L Blake, David E Nichols, Richard B Mailman.   

Abstract

D(2)-like dopamine receptors mediate functional changes via activation of inhibitory G proteins, including those that affect adenylate cyclase activity, and potassium and calcium channels. Although it is assumed that the binding of a drug to a single isoform of a D(2)-like receptor will cause similar changes in all receptor-mediated functions, it has been demonstrated in brain that the dopamine agonists dihydrexidine (DHX) and N-n-propyl-DHX are "functionally selective". The current study explores the underlying mechanism using transfected MN9D cells and D(2)-producing anterior pituitary lactotrophs. Both dopamine and DHX inhibited adenylate cyclase activity in a concentration-dependent manner in both systems, effects blocked by D(2), but not D(1), antagonists. In the MN9D cells, quinpirole and R-(-)-N-propylnorapomorphine (NPA) also inhibited the K(+)-stimulated release of [(3)H]dopamine in a concentration-responsive, antagonist-reversible manner. Conversely, neither DHX, nor its analogs, inhibited K(+)-stimulated [(3)H]dopamine release, although they antagonized the effects of quinpirole. S-(+)-NPA actually had the reverse functional selectivity profile from DHX (i.e., it was a full agonist at D(2L) receptors coupled to inhibition of dopamine release, but a weak partial agonist at D(2L) receptor-mediated inhibition of adenylate cyclase). In lactotrophs, DHX had little intrinsic activity at D(2) receptors coupled to G protein-coupled inwardly rectifying potassium channels, and actually antagonized the effects of dopamine at these D(2) receptors. Together, these findings provide compelling evidence for agonist-induced functional selectivity with the D(2L) receptor. Although the underlying molecular mechanism is controversial (e.g., "conformational induction" versus "drug-active state selection"), such data are irreconcilable with the widely held view that drugs have "intrinsic efficacy".

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023553     DOI: 10.1124/jpet.301.3.1179

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  35 in total

1.  Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy.

Authors:  John A Allen; Julianne M Yost; Vincent Setola; Xin Chen; Maria F Sassano; Meng Chen; Sean Peterson; Prem N Yadav; Xi-ping Huang; Bo Feng; Niels H Jensen; Xin Che; Xu Bai; Stephen V Frye; William C Wetsel; Marc G Caron; Jonathan A Javitch; Bryan L Roth; Jian Jin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-24       Impact factor: 11.205

2.  Receptor conformations involved in dopamine D(2L) receptor functional selectivity induced by selected transmembrane-5 serine mutations.

Authors:  J Corey Fowler; Supriyo Bhattacharya; Jonathan D Urban; Nagarajan Vaidehi; Richard B Mailman
Journal:  Mol Pharmacol       Date:  2012-03-13       Impact factor: 4.436

Review 3.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

4.  D2 Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine.

Authors:  Yudao Shen; John D McCorvy; Michael L Martini; Ramona M Rodriguiz; Vladimir M Pogorelov; Karen M Ward; William C Wetsel; Jing Liu; Bryan L Roth; Jian Jin
Journal:  J Med Chem       Date:  2019-04-18       Impact factor: 7.446

5.  Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor.

Authors:  Jennie L Conroy; R Benjamin Free; David R Sibley
Journal:  ACS Chem Neurosci       Date:  2015-02-20       Impact factor: 4.418

6.  Irving Page Lecture: 5-HT(2A) serotonin receptor biology: interacting proteins, kinases and paradoxical regulation.

Authors:  Bryan L Roth
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

7.  The Gq and G12 families of heterotrimeric G proteins report functional selectivity.

Authors:  Li Zhang; Lawrence F Brass; David R Manning
Journal:  Mol Pharmacol       Date:  2008-10-24       Impact factor: 4.436

8.  Recruitment of beta-arrestin2 to the dopamine D2 receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling.

Authors:  Ib V Klewe; Søren M Nielsen; Louise Tarpø; Eneko Urizar; Concetta Dipace; Jonathan A Javitch; Ulrik Gether; Jan Egebjerg; Kenneth V Christensen
Journal:  Neuropharmacology       Date:  2008-04-08       Impact factor: 5.250

9.  Ligand functional selectivity advances our understanding of drug mechanisms and drug discovery.

Authors:  Richard B Mailman; Vishakantha Murthy
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

Review 10.  Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?

Authors:  Richard B Mailman; Vishakantha Murthy
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.